IndiTreat ® test effectiveness
IndiTreat® – The potential to predict tumor resistance and sensitivity
Until today, there have been no functional means to evaluate the most efficacious form of cancer treatment for the individual patient. Up to 50% of first-line treatments of metastatic colorectal cancer are ineffective mainly due to tumor resistance*, causing a measurable burden on clinic resources and immeasurable patient suffering.
Over the last decade, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality. IndiTreat serves you and your clinic with functional information on tumor resistance and sensitivity.
* European Journal of Cancer 81 (2017) 191–202
What does this mean to oncologists and their patients?
Please contact 2cureX for more information
October 21, 2021
Presentation by Henrik Harling (CMO 2cureX) at the 17. National Congress of Digestive Cancers (Viseu, Portugal)
November 15, 2021
Presentation by Ole Thastrup (CSO 2cureX) at the TechConnect Europe Innovation Conference & Expo (Malmø, Sweden)
November 25, 2021
Q3 2021 Interim Report released
February 24, 2022
Year-End Report 2021